The Phage Advances Personalized Healthcare with New Funding
The Phage, a company specializing in AI-driven analysis of biological data to implement personalized healthcare solutions, has successfully secured ¥570 million in a Series A funding round. The round, which was finalized on October 13, 2026, was led by Itochu Technology Ventures. Other investors in this round include Tokio Marine & Nichido Fire Insurance, Fukui Capital Partners, Genesia Ventures, and Vision Incubate.
Company Overview
Founded with a focus on analyzing the relationship between postprandial blood glucose levels and individual lifestyle behaviors, The Phage utilizes advanced AI models to provide personalized medical and healthcare solutions. Shohei Tokunaga, the CEO, leads the company’s initiatives in using AI solutions to analyze postprandial glucose responses.
Strategic Investment and Alliances
This latest investment will support The Phage's ongoing development of its blood glucose foundation model, which learns from large-scale continuous blood glucose data. The company is exploring the commercial application of this model to predict future blood glucose fluctuations, classify metabolic types, and assess health risks. A notable aspect of this funding round is The Phage's new capital and business alliance with Tokio Marine Holdings. This partnership aims to advance healthcare solutions to prevent severe lifestyle-related diseases.
Use of Funds
The funds raised will be utilized to expand The Phage's AI operational capabilities on a commercial scale, furthering their efforts to offer blood glucose management programs for corporate health insurance and local governments. This expansion follows successful demonstration experiments conducted in collaboration with Fukui Prefecture, where significant improvements in participants' dietary and lifestyle habits were observed.
Location
The Phage operates from its headquarters located at Shibuya Scramble Square in Shibuya, Tokyo.
Shohei Tokunaga, CEO of The Phage, commented on the funding: "This investment enables us to enhance our AI-driven healthcare solutions, paving the way for more personalized and effective health management programs."
The Phage's innovative approach to healthcare analytics positions it well to address critical needs in the healthcare industry, particularly in managing and predicting health outcomes related to blood glucose levels.